QCG
REGN icon

Quadrant Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Quadrant Capital Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.84M Buy
3,677
+60
+2% +$45.9K 0.08% 192
2025
Q4 		$2.79M Buy
3,617
+49
+1% +$33.3K 0.08% 178
2025
Q3 		$2.01M Buy
3,568
+1,564
+78% +$884K 0.07% 250
2025
Q2 		$1.05M Sell
2,004
-688
-26% -$384K 0.04% 457
2025
Q1 		$1.71M Buy
2,692
+1,842
+217% +$1.27M 0.06% 233
2024
Q4 		$605K Sell
850
-167
-16% -$140K 0.04% 281
2024
Q3 		$1.07M Sell
1,017
-1
-0.1% -$1.11K 0.07% 194
2024
Q2 		$1.07M Buy
1,018
+51
+5% +$49.4K 0.08% 178
2024
Q1 		$931K Buy
967
+8
+0.8% +$7.61K 0.07% 195
2023
Q4 		$842K Buy
959
+50
+6% +$41.2K 0.07% 198
2023
Q3 		$748K Sell
909
-2
-0.2% -$1.57K 0.07% 193
2023
Q2 		$655K Sell
911
-45
-5% -$34.7K 0.07% 205
2023
Q1 		$786K Buy
956
+123
+15% +$92.8K 0.08% 181
2022
Q4 		$601K Buy
833
+49
+6% +$36.2K 0.07% 209
2022
Q3 		$540K Buy
784
+149
+23% +$93.8K 0.07% 194
2022
Q2 		$375K Buy
635
+65
+11% +$42.3K 0.05% 271
2022
Q1 		$398K Buy
570
+31
+6% +$19.6K 0.05% 273
2021
Q4 		$340K Buy
539
+28
+5% +$17.2K 0.04% 307
2021
Q3 		$309K Buy
511
+53
+12% +$32.9K 0.04% 285
2021
Q2 		$256K Buy
458
+24
+6% +$12.2K 0.04% 315
2021
Q1 		$205K Buy
434
+110
+34% +$53.6K 0.03% 347
2020
Q4 		$157K Buy
324
+14
+5% +$7.56K 0.03% 363
2020
Q3 		$174K Buy
310
+22
+8% +$13.3K 0.04% 286
2020
Q2 		$180K Sell
288
-407
-59% -$231K 0.04% 288
2020
Q1 		$333K Buy
695
+427
+159% +$176K 0.06% 273
2019
Q4 		$95K Buy
268
+234
+688% +$78.7K 0.01% 1008
2019
Q3 		$7K Sell
34
-474
-93% -$140K ﹤0.01% 1858
2019
Q2 		$154K Buy
508
+152
+43% +$50.6K 0.02% 675
2019
Q1 		$141K Buy
356
+248
+230% +$102K 0.02% 632
2018
Q4 		$32K Buy
108
+53
+96% +$19.4K 0.01% 1040
2018
Q3 		$19K Buy
55
+7
+15% +$2.66K 0.01% 1013
2018
Q2 		$13K Sell
48
-29
-38% -$9.07K ﹤0.01% 1155
2018
Q1 		$23K Sell
77
-22
-22% -$7.65K 0.01% 904
2017
Q4 		$30K Buy
99
+19
+24% +$7.7K 0.01% 778
2017
Q3 		$31K Sell
80
-16
-17% -$7.61K 0.01% 750
2017
Q2 		$38K Buy
96
+54
+129% +$23.6K 0.02% 640
2017
Q1 		$12K Sell
42
-38
-48% -$14.1K 0.01% 1012
2016
Q4 		$24K Buy
80
+8
+11% +$3.04K 0.01% 695
2016
Q3 		$25K Buy
72
+16
+29% +$6.42K 0.02% 671
2016
Q2 		$17K Sell
56
-71
-56% -$27.3K 0.01% 781
2016
Q1 		$41K Buy
127
+60
+90% +$24.7K 0.03% 444
2015
Q4 		$33K Sell
67
-60
-47% -$32.5K 0.02% 452
2015
Q3 		$58K Sell
127
-56
-31% -$30.1K 0.04% 376
2015
Q2 		$91K Buy
+183
New +$89.3K 0.06% 270

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quadrant Capital Group's REGN Position: Q1 2026 in Review

Quadrant Capital Group increased its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q1 2026, buying an estimated $45.9K and bringing the position to 3,677 shares worth $2.84M. The position accounts for 0.08% of the portfolio, ranked #192.

Quadrant Capital Group first reported a position in REGN in Q2 2015 and has held it in 44 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Quadrant Capital Group held 3,677 shares of Regeneron Pharmaceuticals worth $2.84M as of Q1 2026.
  • Quadrant Capital Group bought 60 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $45.9K.
  • Regeneron Pharmaceuticals made up 0.08% of Quadrant Capital Group's portfolio in Q1 2026, its #192 holding.
  • Quadrant Capital Group first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.